

**Infectious Diseases Case Management Conference 2025-2026 - 6/13/2025**

**June 13, 2025**

**8:00 AM - 9:00 AM**

**Target Audience**

This program has been designed for INTERNAL MEDICINE - Infectious Disease, PATHOLOGY - Pathology-Medical Microbiology

**Series Educational Objectives**

After participating in this regularly scheduled series, participants should be able to:

- 1 Describe and generate differential diagnoses in patients presenting with illnesses that could be caused by infectious diseases
- 2 Describe how to improve confidence in understanding the latest modes for diagnostic testing for infectious diseases
- 3 Review the latest treatment options for infectious diseases
- 4 Discuss how to improve communication across clinical teams to improve quality of care and patient safety

**Accreditation**

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Designation of Credit**

**Physicians:** Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**ABIM MOC:** up to 1 MOC points

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

**Nurses:** This activity is for 1.00 contact hours.

**Pharmacists:** This activity is approved for 1.00 contact hours

UAN Number: JA0000324-0000-25-005-L04-P | JA0000324-0000-25-005-L04-T

**PAs:** Penn Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria.

This activity is designated for 1.00 AAPA Category 1 CME credit(s). PAs should only claim credit commensurate with the extent of their participation.

**For more information, please contact  
Stuart Isaacs  
(215) 873-1737  
isaacs@PennMedicine.upenn.edu**

**Check your transcript online at <https://upenn.cloud-cme.com>**

**Approved for (PSRM) patient safety/risk management designation**

**Acknowledgement of Commercial Support\***

None

### Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships (RFRs) that they have with any ineligible company, which is defined as any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Disclosure to learners includes all RFRs for all those in control of content including faculty, planners, moderators, and reviewers.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are evidence-based, are based on valid content, and are independent of control from ineligible companies and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain any financial relationships. Part of the peer review process involved reviewing the content, determining which financial relationships were relevant, and applying appropriate mitigation strategies. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no financial relationships with any ineligible companies. Any peer reviewer who is determined to have a relevant financial relationship must recuse themselves from the peer review process.

| Name of individual           | Individual's role in activity            | Nature of Relationship(s) / Name of Ineligible Company(s)  |
|------------------------------|--|--|
| William R Short, MD          | Other Planning Committee Member          | Advisor-ViiV Healthcare   Grant or research support-Gilead Sciences, Inc - 12/15/2024  |
| Ebbing Lautenbach, MD        | Other Planning Committee Member          | Nothing to disclose - 04/21/2025   |
| Kathleen Degnan, MD          | Other Planning Committee Member          | Grant or research support-Gilead Sciences, Inc - 09/17/2024  |
| Stephen J Gluckman, MD       | Faculty, Other Planning Committee Member | Nothing to disclose - 11/27/2024   |
| Jillian T Baron, MD          | Other Planning Committee Member          | Nothing to disclose - 04/18/2025   |
| Kathryn Whitaker, MD         | Other Planning Committee Member          | Grant or research support-Merck & Co - 10/07/2024  |
| Stuart Isaacs, MD, Physician | Course Director                          | Nothing to disclose - 09/12/2024   |
| Laurel Glaser, MD            | Other Planning Committee Member          | Nothing to disclose - 05/13/2025   |
| Blair C Weikert, MD          | Other Planning Committee Member          | Nothing to disclose - 04/03/2025   |
| Todd Barton, MD              | Other Planning Committee Member          | Nothing to disclose - 10/27/2024   |
| Sarah Longworth, MD          | Other Planning Committee Member          | Nothing to disclose - 02/21/2025   |
| Emily Blumberg, MD           | Other Planning Committee Member          | Grant or research support-Merck & Co (Relationship has ended)   Honoraria-Kamada (Relationship has ended)   Honoraria-Biotest (Relationship has ended)   Grant or research |

|                      |                                 |  |
|----------------------|---------------------------------|--|
|                      |                                 | support-Scynexis Advisor-Aerium (Relationship has ended)  Grant or research support-Hologic (Relationship has ended)  Grant or research support-Takeda Pharmaceuticals Other: DSMB member-Amplyx (Relationship has ended) - 07/24/2024 |
| Amy Graziani, PharmD | Pharmacy Planner                | Nothing to disclose - 09/13/2024   |
| Leah Turner, CRNP RN | Nurse Planner                   | Nothing to disclose - 08/20/2024   |
| Kurt Palumbo, PA-C   | Physician Assistant Planner     | Nothing to disclose - 09/09/2024   |
| Kyle Rodino, PhD     | Other Planning Committee Member | Consulting Fee-bioMerieux Consulting Fee-Diasorin Advisor-DelveBio Consulting Fee-Roche - 03/24/2025   |
| Wei-Teng Yang, MD    | Other Planning Committee Member | Nothing to disclose - 10/23/2024   |

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected